PASG | Passage Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.6000 - 0.7200
52 Week Range	0.4510 - 1.7900
Beta	1.50
Implied Volatility	413.73%
IV Rank	100.00%
Day's Volume	3,152,572
Average Volume	547,934
Shares Outstanding	61,767,300
Market Cap	40,766,418
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-02-28

Valuation
Profitability
Growth
Health
P/E Ratio	-0.56
Forward P/E Ratio	N/A
EPS	-1.17
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	58
Country	USA
Website	PASG

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

PASG's peers: ADCT, ADVM, AKRO, ALEC, ALXO, APVO, BCAB, BCLI, BDTX, CABA, CLLS, CRNX, DARE, DTIL, ETON, EWTX, FDMT, GBIO, GOSS, HOWL, IFRX, IGMS, IPSC, LGND, LIXT, MTNB, NKTX, OMER, RVMD, FIXX, STOK, PLRX, PRLD, PSTX, QSI, RGNX, RNA, SLDB, SRRK, SWTX, SYBX, SYRS, TNGX, XBIT, XOMA, YMAB, THRD, IVVD, OABI, ZVRA, GRI

*Chart delayed

Analyzing fundamentals for PASG we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PASG Fundamentals page.

Watching at PASG technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on PASG Technicals page.